Drug Profile
Research programme: diabetes and obesity therapeutics - Boehringer Ingelheim/ETH Zurich
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in Germany
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in Obesity in Germany